Skip to content
Peptigraph home

Semaglutide for Inflammation: What the Evidence Shows

What human and animal studies show about Semaglutide for inflammation, how strong that evidence is, and what is still unproven.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGLP-1 agonistUpdated
Strongest evidence
Human RCT
Human studies
5
PubMed records, our ledger
Animal studies
0
PubMed records, our ledger
Studies we summarised
2
with an outcome for inflammation

Evidence for inflammation

Each row is an outcome related to inflammation from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Semaglutide for inflammation: outcomes in published studies
OutcomeResultStudy typeSource
Carotid plaque inflammationNo significant difference between semaglutide and placebo in carotid plaque inflammation at week 26.Human RCTn = 101American heart journal 2025, PMID 40345413
C-reactive proteinC-reactive protein changed by -43.5% with semaglutide vs -7.3% with placebo.Human RCTn = 529The New England journal of medicine 2023, PMID 37622681

PubMed records for Semaglutide and inflammation: 5 human, 0 animal (search counts, not studies we reviewed). Grades follow our .

How strong is it?

Strongest evidence:Human RCT evidence, 4 of 4American heart journal 2025, PMID 40345413

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

Inflammation is a marker, not a diagnosis

MedlinePlus says most types of arthritis can cause joint pain and inflammation (swelling).[3]

The one randomised trial built to look at inflammation directly, a PET-MRI study of carotid plaques in people with type 2 diabetes, found no detectable difference between semaglutide and placebo.[1]

Its authors say the trial may have missed an effect because baseline inflammation was minimal, so it does not rule one out.[1]

Blood markers in other trials

In the heart-failure trial of people with obesity, CRP fell 43.5% with semaglutide and 7.3% with placebo.[2]

A pooled analysis of obesity-drug trials in people without diabetes names retatrutide and semaglutide as most effective at lowering C-reactive protein.[4]

A review of sports-medicine peptides says the benefit of semaglutide in knee osteoarthritis is mainly through weight loss, with anti-inflammatory effects only described as putative.[5]

Other peptides people research for inflammation

All peptides for inflammation, compared

Common questions

Does Semaglutide help with inflammation?

The strongest study we summarise for inflammation is human rct evidence, across 2 studies with an outcome for inflammation. A trial result is not an approval; see the legal status.

Is Semaglutide approved for inflammation?

Semaglutide is FDA approved (Ozempic, Wegovy, Rybelsus). Which conditions that approval covers is set by the label; use for anything else is off-label.

What is the best peptide for inflammation?

There is no single answer. Our inflammation overview compares each candidate by evidence grade and legal status rather than by popularity.

Is semaglutide anti-inflammatory?

The evidence is mixed: CRP fell in a heart-failure trial, but a dedicated carotid-plaque inflammation trial found no significant difference from placebo.[1]

Does semaglutide lower CRP?

In the STEP-HFpEF trial the CRP level fell 43.5% with semaglutide against 7.3% with placebo, in people with obesity and heart failure.[2]

More on Semaglutide

Sources

  1. 1Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trial.American heart journal · 2025PMID 40345413Accessed 2 Oct 2026
  2. 2Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.The New England journal of medicine · 2023PMID 37622681Accessed 2 Oct 2026
  3. 3medlineplus.gov pagemedlineplus.gov · web pagemedlineplus.gov
  4. 4Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials.Journal of diabetes · 2025PMID 40207414Accessed 2 Oct 2026
  5. 5Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.JBJS reviews · 2026PMID 42160466Accessed 11 Oct 2026

Found an error? Report a correction.